Journal
CELLS
Volume 8, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/cells8040357
Keywords
beta-3 adrenergic receptor; therapeutic target; G-protein coupled receptors
Categories
Funding
- NIH [NIH RO1 DK072612, NIH PO1 DK-17433]
Ask authors/readers for more resources
The beta-3 adrenergic receptor ((3)-AR) is by far the least studied isotype of the beta-adrenergic sub-family. Despite its study being long hampered by the lack of suitable animal and cellular models and inter-species differences, a substantial body of literature on the subject has built up in the last three decades and the physiology of (3)-AR is unraveling quickly. As will become evident in this work, (3)-AR is emerging as an appealing target for novel pharmacological approaches in several clinical areas involving metabolic, cardiovascular, urinary, and ocular disease. In this review, we will discuss the most recent advances regarding (3)-AR signaling and function and summarize how these findings translate, or may do so, into current clinical practice highlighting (3)-AR's great potential as a novel therapeutic target in a wide range of human conditions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available